Peter J. O’Dwyer

42.1k total citations · 9 hit papers
401 papers, 23.6k citations indexed

About

Peter J. O’Dwyer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter J. O’Dwyer has authored 401 papers receiving a total of 23.6k indexed citations (citations by other indexed papers that have themselves been cited), including 239 papers in Oncology, 151 papers in Molecular Biology and 115 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter J. O’Dwyer's work include Colorectal Cancer Treatments and Studies (93 papers), Cancer Treatment and Pharmacology (56 papers) and Pancreatic and Hepatic Oncology Research (55 papers). Peter J. O’Dwyer is often cited by papers focused on Colorectal Cancer Treatments and Studies (93 papers), Cancer Treatment and Pharmacology (56 papers) and Pancreatic and Hepatic Oncology Research (55 papers). Peter J. O’Dwyer collaborates with scholars based in United States, United Kingdom and France. Peter J. O’Dwyer's co-authors include Keith T. Flaherty, Al B. Benson, Paul J. Catalano, Bruce J. Giantonio, Edith P. Mitchell, K. B. Nolop, Steven R. Alberts, Jeffrey A. Sosman, Richard J. Lee and Grant A. McArthur and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of Biological Chemistry.

In The Last Decade

Peter J. O’Dwyer

389 papers receiving 23.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 2.6k citations Keith T. Flaherty, Peter J. O’Dwyer et al. profile →
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

2007 1.7k citations Bruce J. Giantonio, Paul J. Catalano et al. Journal of Clinical Oncology profile →
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

2011 1.3k citations Gregory L. Beatty, E. Gabriela Chiorean et al. profile →
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →
Phase II Trial of Sorafenib in Advanced Thyroid Cancer

2008 535 citations Vandana G. Abramson, Andrea B. Troxel et al. Journal of Clinical Oncology profile →
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

2015 513 citations Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology profile →
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

2014 409 citations Andrea B. Troxel, Daniel F. Heitjan et al. profile →
Service Robots in the Healthcare Sector

2021 167 citations Peter J. O’Dwyer et al. profile →
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

2022 125 citations Paul J. Catalano, Peter J. O’Dwyer et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Peter J. O’Dwyer

Since Specialization

Citations

This map shows the geographic impact of Peter J. O’Dwyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. O’Dwyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. O’Dwyer more than expected).

Fields of papers citing papers by Peter J. O’Dwyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. O’Dwyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. O’Dwyer. The network helps show where Peter J. O’Dwyer may publish in the future.

Co-authorship network of co-authors of Peter J. O’Dwyer

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. O’Dwyer. A scholar is included among the top collaborators of Peter J. O’Dwyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. O’Dwyer. Peter J. O’Dwyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	242MO Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201 2024 ·Annals of Oncology ·Kristen K. Ciombor, Hong Sun, Calvin Eng, Xin Yao, (unknown), Prajnan Das, A. Bapsi Chakravarthy, Peter J. O’Dwyer	1
2	A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186. 2024 ·Journal of Clinical Oncology ·Efrat Dotan, Paul J. Catalano, Leon Lenchik, Robert D. Boutin, Xin Yao, James Ohr, Kian‐Huat Lim, Namrata Vijayvergia, Sreenivasa R Chandana, Aparna Kalyan, Richard F. Dunne, David B. Zhen, Daneng Li, Melissa A. Simon, Jordan Berlin, Lynne I. Wagner, Peter J. O’Dwyer	4
3	Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H. 2024 ·Journal of Clinical Oncology ·April K.S. Salama, Victoria Wang, Erin Macrae, Jong‐In Park, Helen X. Chen, Robert J. Gray, Lisa M. McShane, Larry Rubinstein, (unknown), Stanley R. Hamilton, Deborah K. Armstrong, James V. Tricoli, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty	1
4	Phase II Trial of Afatinib in Patients With EGFR-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A 2024 ·JCO Precision Oncology ·Scott Gettinger, (unknown), Karen L. Reckamp, Jeffrey A. Moscow, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Xiao–Tang Kong, James V. Tricoli, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, (unknown), Keith T. Flaherty	2
5	Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer 2019 ·Clinical Cancer Research ·Amy S. Clark, Nicholas P. McAndrew, Andrea B. Troxel, Michael D. Feldman, Priti Lal, Mark Rosen, (unknown), Colleen Redlinger, Maryann Gallagher, Angela R. Bradbury, Susan M. Domchek, Kevin R. Fox, Peter J. O’Dwyer, Angela DeMichele	35
6	Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma 2018 ·Clinical Cancer Research ·Jianbo Cao, Stephen Pickup, Cynthia Clendenin, Barbara Blouw, Hoon Choi, David W. Kang, Mark Rosen, Peter J. O’Dwyer, Rong Zhou	23
7	TNF Signaling through RIP1 Kinase Enhances SN38-Induced Death in Colon Adenocarcinoma 2017 ·Molecular Cancer Research ·Lucía Cabal‐Hierro, Peter J. O’Dwyer	16
8	JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to Chemotherapy 2016 ·Molecular Cancer Research ·Irina A. Vasilevskaya, Muthu Selvakumaran, David W. Roberts, Peter J. O’Dwyer	31
9	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer breakdown → 2015 ·Journal of Clinical Oncology ·Scott Kopetz, Jayesh Desai, Emily Chan, J. Randolph Hecht, Peter J. O’Dwyer, Dipen M. Maru, Van K. Morris, Filip Jankú, Arvind Dasari, Woonbok Chung, Jean‐Pierre J. Issa, Peter Gibbs, Brian P. James, Garth Powis, K. B. Nolop, Suman Bhattacharya, Leonard B. Saltz	513
10	Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents 2015 ·Clinical Cancer Research ·Irina A. Vasilevskaya, Muthu Selvakumaran, Lucía Cabal‐Hierro, (unknown), Jeffrey D. Winkler, Peter J. O’Dwyer	22
11	CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment 2014 ·Clinical Cancer Research ·Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gramlich, Maryann Gallagher, Priti Lal, Michael D. Feldman, Paul J. Zhang, Christopher Colameco, David A. Lewis, Melissa Langer, Noah Goodman, Susan M. Domchek, Keerthi Gogineni, Mark Rosen, Kevin R. Fox, Peter J. O’Dwyer	280
12	Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy 2013 ·Clinical Cancer Research ·Muthu Selvakumaran, Ravi K. Amaravadi, Irina A. Vasilevskaya, Peter J. O’Dwyer	182
13	Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial 2013 ·Clinical Cancer Research ·Josep Tabernero, Rocio García‐Carbonero, James T. Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Ірина Давиденко, Ramón Salazar, (unknown), Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, (unknown), Vanessa Potter, (unknown), Nathalie A. Lokker, Peter J. O’Dwyer	69
14	A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma 2013 ·Clinical Cancer Research ·Gregory L. Beatty, Drew A. Torigian, E. Gabriela Chiorean, Babak Saboury, Alex Brothers, Abass Alavi, Andrea B. Troxel, Weijing Sun, Ursina Teitelbaum, Robert H. Vonderheide, Peter J. O’Dwyer	364
15	Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab 2012 ·Clinical Cancer Research ·David O. Bates, Paul J. Catalano, Kirsty E. Symonds, Alexander H. R. Varey, Pramila Ramani, Peter J. O’Dwyer, Bruce J. Giantonio, Neal J. Meropol, Al B. Benson, Steven J. Harper	54
16	Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer 2011 ·Clinical Cancer Research ·Keith T. Flaherty, Patricia LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O’Dwyer, Gary K. Schwartz	295
17	A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis 2009 ·Cancer Research ·Pål Sætrom, Jacob Biesinger, (unknown), David Smith, Laurent F. Thomas, Karim Majzoub, Guillermo E. Rivas, Jessica Alluin, John J. Rossi, Theodore G. Krontiris, Jeffrey N. Weitzel, Mary B. Daly, Al B. Benson, John M. Kirkwood, Peter J. O’Dwyer, Rebecca Sutphen, James A. Stewart, David C. Johnson, Garrett P. Larson	118
18	Phase II Trial of Sorafenib in Advanced Thyroid Cancer breakdown → 2008 ·Journal of Clinical Oncology ·Vandana G. Abramson, Andrea B. Troxel, Anoma Nellore, Kanchan Puttaswamy, Maryann Redlinger, (unknown), Susan J. Mandel, Keith T. Flaherty, Laurie A. Loevner, Peter J. O’Dwyer, Marcia S. Brose	535
19	Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody 2007 ·Journal of Clinical Oncology ·Robert H. Vonderheide, Keith T. Flaherty, Magi Khalil, (unknown), David L. Bajor, Natalie A. Hutnick, Patricia Sullivan, J. J. Mahany, Maryann Gallagher, Amy Kramer, Stephanie Green, Peter J. O’Dwyer, Kelli L. Running, Richard D. Huhn, Scott Antonia	416
20	Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma breakdown → 2006 ·Journal of Clinical Oncology ·Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer	794

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact